Revenue Growth Masks a Profit Collapse: Subsidy Delay and Inventory Impairment Drive 65% PAT Fall
Q2 delivers 7.2% revenue growth but 64.6% profit collapse, driven by ₹6.7 Cr subsidy notification delay and ₹60 Cr inventory impairment. Management has downgraded normalized profitability and confirms capex, but near-term working-capital risk looms.
₹7,364 Cr
+7.2% YoY, +20.2% QoQ
₹121 Cr
-64.6% YoY, -69.2% QoQ
₹5,866
inventory-aided; stock 9L tons
₹5,000
prior call guidance
₹4,500–5,000/ton
-18.6% vs Q2 reported
On paper, Paradeep Phosphates delivered a solid 7.2% revenue top-line in Q2 FY27—₹7,364 Cr, accelerating from a weak Q1. But the bottom line tells a different story. Reported PAT of ₹121 Cr represents a 64.6% collapse from the prior year. The gap between headline and profit is the story: three specific factors explain why this quarter's revenue growth did not flow through to the bottom line.
The three drivers of the profit collapse
First, inventory impairment of ₹60 Cr — a prudent write-down on NBS-linked pricing, as sulphur and ammonia costs have softened. Second, ₹6,700 Cr in subsidy receivables outstanding (₹3,000 Cr billed to government, ₹3,700 Cr pending channel realization). This is not a direct P&L hit, but it locks working capital at a time when inventory stock has ballooned to 9 lakh tons (+18–29% YoY), creating carrying costs and liquidity pressure. Third, the reported EBITDA of ₹431 Cr translates to ₹5,866 per ton — 17% above management's own normalized guidance of ₹5,000/ton. Strip out the inventory benefit, and normalized EBITDA would sit closer to ₹367 Cr, revealing the underlying margin compression.
Inventories which has been, we have taken a position that is lying in the pipeline, which will be liquidated in this Rabi. So we have stocked up, keeping the Rabi in mind.
Strong Rabi season coming; market share +1% farmer sales
ContradictedMonsoon impact -10–15% expected H2, e-token system disrupting farmer adoption, inventory at 9L tons
Q2 revenue ₹7,364 Cr, EBITDA ₹431 Cr, PAT ₹122 Cr (exactly reported)
SupportedNumbers exact; ₹121 Cr PAT vs claimed ₹122 Cr (minor rounding)
EBITDA per ton ₹5,866 reflects healthy 3% YoY improvement
Overstated₹5,866 is 17% above ₹5,000 normalized target; inventory-benefitted
PAT decline solely due to subsidy delay and inventory revaluation
SupportedBoth confirmed; ₹60 Cr impairment + ₹3.7 Cr subsidy channel delay + commodity softening all contribute
What changed on this call
Management has taken two significant steps. First, the H2 FY27 EBITDA/ton guidance has been downgraded to ₹4,500–5,000 (vs Q2's reported ₹5,866) — an implicit admission that Q2's per-ton metrics were inventory-flattered and that normalized profitability is lower. Second, backward integration capex has been reconfirmed at ₹4,000–4,700 Cr through 2029, with phosphoric acid Phase-I (ramp from 5 to 7 lakh tons) targeted for Q1 FY28 and a 1 lakh ton milestone by December 2026. The company has also provided a post-capex target of ₹4,800–5,000 EBITDA/ton, implying an incremental ₹1,500/ton uplift from integration. Notably, no absolute FY27 revenue or PAT guidance was disclosed — management reiterated its standard 'typically don't give guidance' line — leaving visibility limited to per-ton metrics and volume bands.
Revenue +7.2% YoY; H1 FY27 tracking 19% growth on ₹13,488 Cr
Farmer market share +1% YoY despite monsoon and e-token headwinds
Phosphoric acid backward integration on track; 1L ton milestone by Dec 2026
Capex EBITDA/ton target (₹4,800–5,000) provides 18–24 month growth catalyst
₹60 Cr inventory impairment + ₹6,700 Cr subsidy outstanding (working capital stress)
H2 EBITDA/ton guidance down 18.6% (₹4,500–5,000 vs Q2's ₹5,866)
Monsoon impact -10–15% and e-token adoption lag threaten Rabi recovery
No absolute FY27 revenue/PAT guidance; visibility limited to per-ton metrics
Subsidy receivable realization delay
High₹6,700 Cr outstanding (₹3,700 Cr in channel). 60–70 day lag post-farmer sale. If NBS notification delayed beyond H2, working-capital strain and potential covenant breach. October collections of ₹1,200 Cr are tracking, but Dec/Jan realization is critical.
Inventory impairment and obsolescence
High₹60 Cr write-down already taken; stock 9L tons (+18–29% YoY) at risk if Rabi demand disappoints or monsoon is weak. Further write-downs possible if NBS notification delays or farmer preference shifts to DAP (lower-margin).
Volume and demand volatility
MediumMonsoon deficit -10–15%, e-token system disrupting farmer adoption, government subsidy policy shifting demand from NPK to DAP (unfavorable mix). H2 volume guidance vague ('₹4M–4.2M tons', equivalent to prior year). If Rabi fails, full-year volume/profit will miss.
Capex execution and backward integration ramp
Medium₹4,700 Cr capex over 2029, Phase-I commissioning Q1 FY28. Dependent on commodity recovery (sulphur, ammonia) and execution. If integration ramp slips or capex unit cost overspends, post-capex EBITDA/ton target (₹4,800–5,000) may not materialize.
Commodity pricing and forex volatility
LowSulphur/ammonia currently softening (₹850–880), aiding capex unit costs. If geopolitics or supply shifts reverse pricing, backward integration EBITDA uplift may not deliver. INR depreciation adds cost to imported DAP/NPK.
The street's view
The stock is trading at ₹143.91, down 38.6% from its all-time high of ₹234.39 and up 44.3% from its 52-week low. It sits below its 50-day and 200-day simple moving averages at ₹148.2 and ₹134.65 respectively, suggesting weakness but not capitulation. Critically, FII ownership has trimmed sharply from 8.36% in Q4 FY27 to 5.10% in Q1 (a drop of 3.26 percentage points), while DII has stepped in modestly (18.08% vs 15.49% prior quarter). Promoter holding remains stable at 57.86%. Bulk trading activity in mid-July 2026 (institutional players MICROCURVES TRADING and QE SECURITIES at ₹154–155 levels) suggests positioning ahead of earnings; no promoter selling has been detected. The market's own verdict on this print: cautious at best, with foreign investors pulling back on near-term uncertainty.
1 · Oct–Nov 2026: Rabi subsidy notification and NBS lifting
The critical gate. ₹3,700 Cr in channel subsidy realization and NBS pricing notification will unlock inventory liquidation and normalize margins. If delayed into Q4, working-capital stress will extend and cash conversion will falter.
2 · December 2026: Phosphoric acid Phase-I milestone (1 lakh ton ramp)
Management guidance says 1 lakh ton by December. This is the first proof point on capex execution and backward integration credibility. If it slips, the full ₹4,700 Cr project timeline is at risk.
3 · Q1 FY28: Backward integration commissioning and EBITDA/ton target
Full phosphoric acid Phase-I expected by Q1 FY28 (18 months from now). Watch whether post-capex EBITDA/ton reaches ₹4,800–5,000 as guided, or if commodity recovery/execution underwhelms. This is the step-change catalyst.
Paradeep Phosphates delivered on revenue but stumbled on profitability in Q2 — not because of operational failure, but because of balance-sheet and timing headwinds (subsidy delay, inventory impairment, margin normalization). The company has been transparent about the challenges and has a concrete capex roadmap, which is confidence-building. But near-term, the stock is pinned to two binary events: subsidy realization (Oct–Nov 2026) and inventory liquidation (Rabi season). If both land as expected, margins normalize to ₹4,500–5,000/ton in H2, and the narrative shifts to capex execution and long-term value creation.
Rating: Hold. The stock is fairly priced at current levels, balancing near-term working-capital risk against long-term capex upside. For new money, wait for evidence of subsidy realization (Nov collections) and NBS notification. For holders, hold through the catalyst window. The number to track from here is normalized EBITDA per ton — management has guided ₹4,500–5,000 for H2 FY27 and ₹4,800–5,000 post-capex. If Q3 comes in at the low end of that band, the bear case gains traction.
Informational and educational content only. Not investment advice.